Triclabendazole in the treatment of human fascioliasis: a community-based study
H El Morshedy, A Farghaly, S Sharaf… - … Health Journal, 5 (5) …, 1999 - apps.who.int
H El Morshedy, A Farghaly, S Sharaf, L Abou Basha, R Barakat
EMHJ-Eastern Mediterranean Health Journal, 5 (5), 888-894, 1999, 1999•apps.who.intThe efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A
total of 134 asymptomatic cases of established Fasciola infection were treated: 68
individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10
mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the
first group and 93.9% of the second group were cured. The drug was well tolerated; no
serious side-effects were noted. One patient developed biochemical cholestasis the third …
total of 134 asymptomatic cases of established Fasciola infection were treated: 68
individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10
mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the
first group and 93.9% of the second group were cured. The drug was well tolerated; no
serious side-effects were noted. One patient developed biochemical cholestasis the third …
The efficacy of triclabendazole in the treatment of chronic Fasciola infection was assessed. A total of 134 asymptomatic cases of established Fasciola infection were treated: 68 individuals received a single dose of 10 mg/kg and 66 individuals received 2 doses of 10 mg/kg on 2 consecutive days. Cure was assessed 5 weeks after treatment and 79.4% of the first group and 93.9% of the second group were cured. The drug was well tolerated; no serious side-effects were noted. One patient developed biochemical cholestasis the third day after treatment, but her enzyme profiles returned to normal after 2 months. We conclude triclabendazole is a safe and potent fasciolicidic drug
apps.who.int
以上显示的是最相近的搜索结果。 查看全部搜索结果